Senate Committee holds hearing on ‘Medication and Performance Enhancing Drugs in Horse Racing’

from the U.S. Senate Committee on Commerce, Science, and Transportation website

Washington, DC — On Thursday (July 12), the U.S. Senate Committee on Commerce, Science, and Transportation held a hearing on “Medication and Performance Enhancing Drugs in Horse Racing.”

The hearing examined the prevalence and use of medications and performance enhancing drugs in horse racing.

Eight prominent horse racing industry representatives participated in the hearing.

Panel 1: Mr. Barry Irwin, Chief Executive Officer, Team Valor International; Mr. Kent H. Stirling, Executive Director, Florida Horsemen’s Benevolent & Protective Association, Chairman, Medication Committee, National Horsemen’s Benevolent & Protective Association; Mr. Jeffrey Gural, Chairman, Newmark Grubb Knight Frank, Chairman and Managing Partner, American Racing and Entertainment, LLC; and Mr. Jim Gagliano, President, The Jockey Club.

Panel 2: Mr. Matthew Witman, National Director, American Quarter Horse Association; Mr. Marc Paulhus, Former Director of Equine Protection and Vice President, Humane Society; Mr. Ed Martin, President and CEO, Association of Racing Commissioners International; and Dr. Sheila Lyons, DVM, Founder and Director, The American College of Veterinary Sports Medicine and Rehabilitation Founder and Director, Homecoming Farm, Inc.

The archived hearing as well as the submitted testimony from the eight panelists, the majority statement from Committee Chairman Senator John D. Rockefeller IV, and the opening statement from Senator Tom Udall can be seen here.

Back to Top

Share via